CoChat

IL‐22 and IL‐22 binding protein (IL‐22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections

Open access
Sertorio, Mathieu, Hou, Xunya, Carmo, Rodrigo F., Dessein, Hélia, Cabantous, Sandrine, Abdelwahed, Mohammed, Romano, Audrey, Albuquerque, Fernanda, Vasconcelos, Luydson, Carmo, Theomira, Li, Jun, Varoquaux, Arthur, Arnaud, Violaine, Oliveira, Pablo, Hamdoun, Anas, He, Hongbin, Adbelmaboud, Suzan, Mergani, Adil, Zhou, Jie, Monis, Ahmed, Pereira, Leila Beltrao, Halfon, Philippe, Bourlière, Marc, Parana, Raymundo, dos Reis, Mitermayer, Gonnelli, David, Moura, Patricia, Elwali, Nasr Eldin, Argiro, Laurent, Li, Yuesheng, Dessein, Alain · 2015 · Hepatology
Cited by 78

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Interleukin (IL)‐22 acts on epithelia, hepatocytes, and pancreatic cells and stimulates innate immunity, tissue protection, and repair. IL‐22 may also cause inflammation and abnormal cell proliferation. The binding of IL‐22 to its receptor is competed by IL‐22 binding protein (IL‐22BP), which may limit the deleterious effects of IL‐22. The role of IL‐22 and IL‐22BP in chronic liver diseases is unknown. We addressed this question in individuals chronically infected with schistosomes or hepatitis C virus (HCV). We first demonstrate that schistosome eggs stimulate production of IL‐22 transcripts and inhibit accumulation of IL22‐BP transcripts in schistosome‐infected mice, and that schistosome eggs selectively stimulate production of IL‐22 in cultures of blood leukocytes from individuals chronically infected with Schistosoma japonicum. High IL‐22 levels in cultures correlated with protection against hepatic fibrosis and portal hypertension. To test further the implication of IL‐22/IL‐22BP in hepatic disease, we analyzed common genetic variants of IL22RA2, which encodes IL‐22BP, and found that the genotypes, AA, GG of rs6570136 (P = 0.003; odds ratio [OR] = 2), and CC, TT of rs2064501 (P = 0.01; OR = 2), were associated with severe fibrosis in Chinese infected with S. japonicum. We confirmed this result in Sudanese (rs6570136 GG [P = 0.0007; OR = 8.2], rs2064501 TT [P = 0.02; OR = 3.1]), and Brazilians (rs6570136 GG [P = 0.003; OR = 26], rs2064501 TC, TT (P = 0.03; OR = 11]) infected with S. mansoni. The aggravating genotypes were associated with high IL22RA2 transcripts levels. Furthermore, these same variants were also associated with HCV‐induced fibrosis and cirrhosis (rs6570136 GG, GA [P = 0.007; OR = 1.7], rs2064501 TT, TC (P = 0.004; OR = 2.4]). Conclusions: These results provide strong evidence that IL‐22 protects against and IL‐22BP aggravates liver fibrosis and cirrhosis in humans with chronic liver infections. Thus, pharmacological modulation of IL‐22 BP may be an effective strategy to limit cirrhosis. (H epatology 2015;61:1321–1331)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.27629

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 78

Metadata

Authors
Sertorio, M., Hou, X., Carmo, R. F., Dessein, H., Cabantous, S., Abdelwahed, M., Romano, A., Albuquerque, F., Vasconcelos, L., Carmo, T., Li, J., Varoquaux, A., Arnaud, V., Oliveira, P., Hamdoun, A., He, H., Adbelmaboud, S., Mergani, A., Zhou, J., Monis, A., Pereira, L. B., Halfon, P., Bourlière, M., Parana, R., dos Reis, M., Gonnelli, D., Moura, P., Elwali, N. E., Argiro, L., Li, Y., & Dessein, A.
Venue
Hepatology
Published
2015-03-10
Volume
61
Issue
4
Pages
1321-1331
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2086757562
Cited by
78
References
5
FWCI
6.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.